{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:38:40Z","timestamp":1789958320109,"version":"4.0.1"},"reference-count":16,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2014,6,6]],"date-time":"2014-06-06T00:00:00Z","timestamp":1402012800000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2014,6]]},"abstract":"\n Objective<\/jats:title>\n \n \n \n \n To evaluate the safety and efficacy of epidermal growth factor receptor (\n EGFR<\/jats:styled-content>\n )\u2010targeted therapy in patients with advanced penile or scrotal cancer.\n <\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Patients and Methods<\/jats:title>\n \n \n \n We retrospectively reviewed the charts of patients with penile or scrotal squamous cell carcinoma who had visited our tertiary cancer centre between 2002 and 2009, including their subsequent treatment and follow\u2010up.<\/jats:p>\n <\/jats:list-item>\n \n \n We collected details of\n EGFR<\/jats:styled-content>\n \u2010targeted therapy and clinical outcomes. Treatment\u2010associated time\u2010to\u2010disease\u2010progression (\n TTP<\/jats:styled-content>\n ), overall survival (\n OS<\/jats:styled-content>\n ), responses to therapy and toxicity were evaluated.\n <\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n \n \n \n A total of 24 patients had received\n EGFR<\/jats:styled-content>\n \u2010targeted therapies, including cetuximab, erlotinib and gefitinib. The most common treatment given (to 67% of patients) was cetuximab combined with one or more cytotoxic drugs.\n <\/jats:p>\n <\/jats:list-item>\n \n \n The most common adverse effect was skin rash (71%). The median (range)\n TTP<\/jats:styled-content>\n and\n OS<\/jats:styled-content>\n were 11.3 (1\u201340) and 29.6 (2\u2013205) weeks, respectively. The\n OS<\/jats:styled-content>\n time for patients with visceral or bone metastases was significantly shorter than it was for those without (24.7 vs 49.9 weeks,\n P<\/jats:italic>\n = 0.013).\n <\/jats:p>\n <\/jats:list-item>\n \n Among 17 patients treated with cetuximab alone or in combination with cisplatin, there were four partial responses (23.5%) including two patients with apparently chemotherapy\u2010resistant tumours.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n \n \n Our results suggest that cetuximab has antitumour activity in metastatic penile cancer, and may enhance the effect of cisplatin\u2010based chemotherapy.<\/jats:p>\n <\/jats:list-item>\n \n \n Prospective studies of\n EGFR<\/jats:styled-content>\n \u2010targeted therapies in men with these tumours are warranted.\n <\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/bju.12450","type":"journal-article","created":{"date-parts":[[2013,9,5]],"date-time":"2013-09-05T08:19:07Z","timestamp":1378369147000},"page":"871-877","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":110,"title":["Epidermal growth factor receptor\u2010targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis"],"prefix":"10.1111","volume":"113","author":[{"given":"Bradley C.","family":"Carthon","sequence":"first","affiliation":[{"name":"Department of Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaan S.","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Radiology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis A.","family":"Pettaway","sequence":"additional","affiliation":[{"name":"Department of Urology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance C.","family":"Pagliaro","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,6,6]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(04)01427-5"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)36126-8"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-008-0310-z"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-008-0364-y"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.20414"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn149"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.5477"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.11.038"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00120-009-2101-6"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.v17i1.471"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.8367"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)68815-5"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.1735"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2011.09.001"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2013.783571"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.12.040"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbju.12450","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.12450","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:59:09Z","timestamp":1761742749000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.12450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["10.1111\/bju.12450"],"URL":"https:\/\/doi.org\/10.1111\/bju.12450","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"2014-06-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}